Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

OPKO Health Inc (NASDAQ:OPK)

10.93
Delayed Data
As of Dec 07
 -0.40 / -3.53%
Today’s Change
7.12
Today|||52-Week Range
11.85
+8.76%
Year-to-Date
Weekly CEO Buys Highlights
Dec 05 / GuruFocus News - Paid Partner Content
OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.
Nov 25 / Zacks.com - Paid Partner Content
Opko Health: Rayaldee Makes This Stock Worth Watching
Dec 01 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close11.33
Today’s open11.23
Day’s range10.88 - 11.33
Volume4,608,992
Average volume (3 months)3,380,246
Market cap$6.3B
Dividend yield--
Data as of 3:59pm ET, 12/07/2016

Growth & Valuation

Earnings growth (last year)+85.37%
Earnings growth (this year)-40.00%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+439.63%
P/E ratioNM
Price/Sales9.97
Price/Book3.12

Competitors

 Today’s
change
Today’s
% change
JAZZJazz Pharmaceuticals...-3.28-3.16%
UTHRUnited Therapeutics ...-5.22-3.82%
IONSIonis Pharmaceutical...-1.45-3.06%
MNKMallinckrodt Plc-2.36-4.39%
Data as of 4:03pm ET, 12/07/2016

Financials

Next reporting dateMarch 6, 2017
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$491.7M
Annual profit (last year)-$30.0M
Net profit margin-6.11%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Phillip Frost
Chief Financial Officer, Treasurer, CAO &
SVP
Adam E. Logal
Corporate headquarters
Miami, Florida

Forecasts


Search for Jobs